CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure/hypertension and heart failure.
CVRx® pioneers unique therapies that harness and harmonize the body's natural systems, benefiting society and making CVRx® a universal role model in healthcare. Its vision is to advance health for people everywhere, giving each patient a fuller life.
CVRx was founded in 2001 by Robert Kieval and is based in Minneapolis, Minnesota.
CVRx® developed a proprietary implantable technology for the treatment of heart failure and high blood pressure. BAROSTIM NEO™ uses CVRx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. It also offers Rheos programmer system that communicates with the Rheos pulse generator.
CVRx® has a total of 79 issued patents worldwide: 62 issued in the US and 17 issued elsewhere in the world.
CVRx is backed by Johnson & Johnson Development Corporation, Oxford Finance LLC, New Enterprise Associates, Silicon Valley Bank, Strategic Healthcare Investment Partners, Ysios Capital and others. The company raised $50M in a new equity round on Jul 07, 2020. This brings CVRx's total funding to $390.6M to date.
CVRx® has received numerous awards throughout the years. This include MDDI 2016; 2014 Life Saving BREAKTHROUGH OF THE YEAR by EY; Harry Goldblatt Award in 2014 and many more.